Myelodysplastic syndrome (MDS) are a heterogeneous group of hematological malignancies. Currently, in addition to demethylated chemotherapy and hematopoietic stem cell transplantation, MDS patient-derived mesenchymal stem cells (MDS-MSC) play an important role in understanding the pathogenesis of MDS and related therapeutic targets. For example, abnormal expression of DICER1 gene, abnormalities of PI3K/AKT and Wnt/β-catenin signaling pathways provide new therapeutic targets for MDS. In addition, MDS-MSC is also affected by abnormal microenvironment of the body, such as inflammatory factor S100A9, as well as hypercoagulation and iron overload. In this review, genes, signaling pathways, cytokines, hematopoietic microenvironment, and the effect of therapeutic drugs for MDS-MSC were briefly summarized.
题目: 骨髓增生异常综合征患者来源间充质干细胞的最新研究进展.
摘要: 骨髓增生异常综合征（MDS）是一组异质性的血液系统恶性肿瘤，目前除了去甲基化的化学疗法及造血干细胞移植外，针对MDS患者来源的间充质干细胞（MDS-MSC）开展的研究对了解MDS的发病机制及相关治疗靶点发挥着不可忽视的作用，如DICER1基因的异常表达、PI3K/AKT和Wnt/β-catenin信号通路的异常都为MDS提供新的治疗靶点，除此之外MDS-MSC也受到机体异常微环境如S100A9炎症因子以及高凝、高铁负荷的影响。本文针对MDS-MSC在基因、信号通路、细胞因子、造血微环境以及受治疗药物影响等方面的最新研究进行综述。.
Keywords: cytokine; gene; mesenchymal stem cell; microenvironment; myelodysplastic syndrome; signaling pathway.